Evidence map›Paper›PMID 35837344›Full record

ReviewBiomaterials translational2022

Manufacturing artificial bone allografts: a perspective.

Emma Steijvers, Armaan Ghei, Zhidao Xia

Abstract readReview
In one paragraph

Review in Biomaterials translational, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Article
  2. Review
  3. Coordination-Driven CuAdvanced healthcare materials · 2026
    Article
  4. Biodegradable MgBioactive materials · 2026
    Article
  5. Article
  6. Bone regenerative capacity of the newly synthesized material QG3030: anJournal of periodontal & implant science · 2026
    Article
  7. Article
  8. Bone Grafts: Everything You Need to Know.Journal of periodontal research · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Emma SteijversCentre for Nanohealth, Institute of Life Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, UK.
Armaan GheiCentre for Nanohealth, Institute of Life Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, UK.
Zhidao XiaCentre for Nanohealth, Institute of Life Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone grafts have traditionally come from four sources: the patients' own tissue (autograft), tissue from a living or cadaveric human donor (allograft), animal donors (xenograft) and synthetic artificial biomaterials (ceramics, cement, polymers, and metal). However, all of these have advantages and drawbacks. The most commercially successful bone grafts so far are allografts, which hold 57% of the current bone graft market; however, disease transmission and scarcity are still significant drawbacks limiting their use. Tissue-engineered grafts have great potential, in which human stem cells and synthetical biomaterials are combined to produce bone-like tissue in vitro, but this is yet to be approved for widespread clinical practice. It is hypothesised that artificial bone allografts can be mass-manufactured to replace conventional bone allografts through refined bone tissue engineering prior to decellularisation. This review article aims to review current literature on (1) conventional bone allograft preparation; (2) bone tissue engineering including the use of synthetic biomaterials as bone graft substitute scaffolds, combined with osteogenic stem cells in vitro; (3) potential artificial allograft manufacturing processes, including mass production of engineered bone tissue, osteogenic enhancement, decellularisation, sterilisation and safety assurance for regulatory approval. From these assessments, a practical route map for mass production of artificial allografts for clinical use is proposed.

Indexed as

biomaterialsbone graftdecellularisationstem cellstissue engineering

Identifiers

PMID35837344
PMCPMC9255790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.